Idelalisib Not Yet Recruiting Phase 1 Trials for Chronic Lymphocytic Leukemia (CLL) - Refractory / Relapsed Chronic Lymphocytic Leukemia / Chronic Lymphocytic Leukaemia (CLL) Treatment

IndicationsStatusPurposePhase
Not Yet RecruitingTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT03639324Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL